BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu J, Ma S, Tian S, Zhang M, Ding X, Liu Y, Yang F, Hu Y, Xuan G, Zhou X, Wang J, Han Y. Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes. Front Cell Dev Biol 2021;9:700553. [PMID: 34671598 DOI: 10.3389/fcell.2021.700553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu Y, Ding S, Xu X, Yan D, Fan Y, Ruan B, Zhang X, Zheng L, Jie W, Zheng S. Integrating Network Pharmacology and Bioinformatics to Explore the Effects of Dangshen (Codonopsis pilosula) Against Hepatocellular Carcinoma: Validation Based on the Active Compound Luteolin. Drug Des Devel Ther 2023;17:659-73. [PMID: 36883114 DOI: 10.2147/DDDT.S386941] [Reference Citation Analysis]
2 Huang Y, Zou Y, Tian Y, Yang Z, Hou Z, Li P, Liu F, Ling J, Wen Y. N6-methylandenosine-related immune genes correlate with prognosis and immune landscapes in gastric cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1009881] [Reference Citation Analysis]
3 Luo H, Jiang Q, Luo Y, Yang M, Yu Y, Yu C, Wang X. Comprehensive analysis of ESR1-related ceRNA axis as a novel prognostic biomarker in hepatocellular carcinoma. Epigenomics 2022;14:1393-409. [PMID: 36695093 DOI: 10.2217/epi-2022-0291] [Reference Citation Analysis]
4 Xu L, Yang H, Yan M, Li W. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma. Clin Exp Med 2022. [PMID: 36169759 DOI: 10.1007/s10238-022-00897-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]